Trial Profile
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 07 Oct 2018 Status changed from active, no longer recruiting to completed, according to the results presented at the IDWeek 2018.
- 07 Oct 2018 Results presented at the IDWeek 2018
- 16 Apr 2018 Planned End Date changed from 31 Dec 2017 to 1 May 2018.